Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis
IntroductionThe use of immune checkpoint inhibitors (ICIs) as a front-line treatment for metastatic renal cell carcinoma (RCC) has significantly improved patient’ outcome. However, little is known about the efficacy or lack thereof of immunotherapy after prior use of anti-PD1/PD-L1 or/and anti-CTLA...
Main Authors: | Maria Papathanassiou, Ioannis Tamposis, Kalliopi K. Exarchou-Kouveli, Panagiota I. Kontou, Anna Tzortzi de Paz, Lampros Mitrakas, Maria Samara, Pantelis G. Bagos, Vassilios Tzortzis, Panagiotis J. Vlachostergios |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.996553/full |
Similar Items
-
Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
by: Kyoichi Kaira, et al.
Published: (2021-03-01) -
Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition [version 2; peer review: 2 approved]
by: Maria Samara, et al.
Published: (2024-06-01) -
Hypoxia-Inducible Factor-2-Altered Urothelial Carcinoma: Clinical and Genomic Features
by: Panagiotis J. Vlachostergios, et al.
Published: (2022-11-01) -
Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma
by: Iraklis C. Mitsogiannis, et al.
Published: (2022-09-01) -
DNA Repair Gene Polymorphisms and Susceptibility to Urothelial Carcinoma in a Southeastern European Population
by: Maria Samara, et al.
Published: (2021-05-01)